Nippon India PHARMA Fund - G

NAV ₹499.684 ↑ 6.45 (1.31 %) as on 28 Apr 25

Table of Contents

Scheme Objective
NAV Price Chart
Returns
- Historical Returns
- Compounded Returns
Growth Of 10k Over Years
Holdings / Portfolio
All Plan & Options
Fund Manager Information
Custodians
Registrar & Transfer Agent (RTA)
Administrator Companies
Auditors

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 20.6% since its launch. Ranked 35 in Sectoral category. Return for 2024 was 34% , 2023 was 39.2% and 2022 was -9.9% .

Below is the key information for Nippon India Pharma Fund

NAV as on 28 Apr 25	₹499.684 ↑ 6.45 (1.31 %)
Net Assets (AUM) as on 31 Mar 2025	₹8,081 Cr.
Launch Date	5 Jun 2004
Category	Equity - Sectoral
Rating	☆☆
Type	Open Ended Fund
Risk	High
AMC	Nippon Life Asset Management Ltd.

Alpha Ratio	-4.46
Expense Ratio	1.88 %
Sharpe Ratio	0.353
Information Ratio	-0.49
Benchmark	Not Available
Min Investment	₹5,000
Min SIP Investment	₹100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

NAV Price Chart

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Apr 25

Duration	Returns
1 Month	3.8%
3 Month	7.3%
6 Month	-2.1%
1 Year	16.5%
3 Year	20.2%
5 Year	22.7%
10 Year
15 Year
Since launch	20.6%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

Year	Returns
2023	34%
2022	39.2%
2021	-9.9%
2020	23.9%
2019	66.4%
2018	1.7%
2017	3.6%
2016	7.6%
2015	-10.6%

Growth of 10k Over Years

Date	Value
31 Mar 20	₹10,000
31 Mar 21	₹17,447
31 Mar 22	₹20,234
31 Mar 23	₹18,871
31 Mar 24	₹29,909
31 Mar 25	₹33,564

Asset Allocation

Asset Class	Value
Cash	0.54%
Equity	99.46%

Sector Allocation

Sector	Value
Health Care	99.46%

Top Securities Holdings / Portfolio

Holdings/Securities

Name	Global Industry	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 09 \| SUNPHARMA	Drug Manufacturers - Specialty & Generic	13%	₹1,085 Cr	6,256,349 ↓ -300,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	Drug Manufacturers - Specialty & Generic	9%	₹750 Cr	1,298,808
Lupin Ltd (Healthcare) Equity, Since 31 Aug 08 \| 500257	Drug Manufacturers - Specialty & Generic	7%	₹588 Cr	2,898,126 ↓ -200,000
Cipla Ltd (Healthcare) Equity, Since 31 May 08 \| 500087	Drug Manufacturers - Specialty & Generic	6%	₹462 Cr	3,200,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Sep 20 \| APOLLOHOSP	Medical Care Facilities	5%	₹429 Cr	648,795
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 30 Jun 11 \| DRREDDY	Drug Manufacturers - Specialty & Generic	5%	₹419 Cr	3,662,170
GlaxoSmithKline Pharmaceuticals Ltd (Healthcare) Equity, Since 31 Aug 22 \| GLAXO	Drug Manufacturers - General	4%	₹291 Cr	1,011,921
Vijaya Diagnostic Centre Ltd (Healthcare) Equity, Since 30 Sep 21 \| 543350	Diagnostics & Research	4%	₹285 Cr	2,831,564 ↓ -11,667
Abbott India Ltd (Healthcare) Equity, Since 31 May 11 \| ABBOTINDIA	Drug Manufacturers - Specialty & Generic	3%	₹279 Cr	90,933 ↓ -5,052
Medplus Health Services Ltd (Healthcare) Equity, Since 30 Nov 22 \| 543427	Pharmaceutical Retailers	3%	₹276 Cr	3,627,277

1 - 10 of 40

Ready to Invest?
Talk to our investment specialist

Fund Managers

Name	Since	Tenure
Sailesh Raj Bhan	1 Apr 05	20.01 Yr.
Kinjal Desai	25 May 18	6.86 Yr.

Custodians

Company	Address
Deutsche Bank AG	Deutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Ltd
Address	138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat
FAX	N.A
Email	N.A

Administrator Companies

Company	Address
Nippon India Mutual Fund	9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

Company	Address
Haribhakti & Co. Chartered Accountants	42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and Plan	NAV	6 Month	1 Year	3 Year	5 Year
Nippon India Pharma Fund Normal Dividend, Payout	₹116.464 ↑ 1.50	-2.92 %	15.5 %	19.53 %	25.25 %
Nippon India Pharma Fund Normal Dividend, Reinvestment	₹116.464 ↑ 1.50	-2.92 %	15.5 %	19.53 %	25.25 %
Nippon India Pharma Fund Growth	₹499.684 ↑ 6.45	-2.11 %	16.46 %	20.16 %	22.71 %
Data as on 28 Apr 25

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.

Shepard Technologies Pvt. Ltd : 1808, Solus, Hiranandani Estate, Thane, Maharashtra - 400607

AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153

Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund, or designing a portfolio that suits your needs.

Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.